Zhou Yan, Yu Yusheng, Tang Zheng, Li Shijun, Hu Weixin, Luo Chunlei, Liu Zhihong
Research Institute of Nephrology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu 210002, P.R. China.
Exp Ther Med. 2015 Dec;10(6):2253-2258. doi: 10.3892/etm.2015.2799. Epub 2015 Oct 14.
The aim of the present study was to evaluate the clinical efficacy of peritoneal dialysis (PD) in patients with severe lupus nephritis (LN) complicated with organ dysfunction. In total, 13 severe LN patients complicated with multiple-organ dysfunction, who underwent PD treatment between November 2003 and September 2010, were enrolled in the study. Six patients received methylprednisolone pulse therapy due to lupus activity and progressive renal failure. These patients were complicated with severe edema, cardiac insufficiency and severe hypoalbuminemia. PD was applied to the patients, followed by the administration of immunosuppressants. Patients were followed-up to review the parameters of renal function, the immunological indexes and the systemic lupus erythematosus disease activity index. The results indicated that the general state of health was markedly improved following PD treatment, with edema abatement and improvement of heart function and physical strength. Serum creatinine levels significantly decreased from 6.3±1.6 to 2.6±1.0 mg/dl. A total of 10 cases ceased PD treatment during the follow-up, while three cases continued PD to the end of the follow-up period. The levels of albumin and hemoglobin exhibited a marked increase from 29.7±5.7 to 35.2±5.5 g/l and 8.7±1.8 to 9.8±1.8 g/l, respectively. There was one case of peritonitis, one case of peritoneal leakage and two cases of pneumonia. Therefore, PD may be a successful treatment method for severe LN patients complicated with essential organ dysfunction. PD not only improved the symptoms of edema and heart failure, but also played an important role in preserving residual renal function and improving the nutritional state of the patients. Thus, PD can be considered as a treatment option for patients with severe LN associated with acute kidney injury, however, selecting a suitable immunosuppressant during PD treatment is essential.
本研究的目的是评估腹膜透析(PD)对重症狼疮性肾炎(LN)合并器官功能障碍患者的临床疗效。共有13例在2003年11月至2010年9月期间接受PD治疗的重症LN合并多器官功能障碍患者纳入本研究。6例患者因狼疮活动和进行性肾衰竭接受甲泼尼龙冲击治疗。这些患者合并严重水肿、心功能不全和严重低白蛋白血症。对患者实施PD治疗,随后给予免疫抑制剂。对患者进行随访,以复查肾功能参数、免疫指标和系统性红斑狼疮疾病活动指数。结果表明,PD治疗后患者的总体健康状况明显改善,水肿减轻,心功能和体力得到改善。血清肌酐水平从6.3±1.6显著降至2.6±1.0mg/dl。随访期间共有10例患者停止PD治疗,3例患者持续PD至随访结束。白蛋白和血红蛋白水平分别从29.7±5.7显著升至35.2±5.5g/l和从8.7±1.8显著升至9.8±1.8g/l。发生1例腹膜炎、1例腹膜渗漏和2例肺炎。因此,PD可能是治疗重症LN合并重要器官功能障碍患者的一种成功治疗方法。PD不仅改善了水肿和心力衰竭症状,而且在保留残余肾功能和改善患者营养状况方面发挥了重要作用。因此,PD可被视为重症LN合并急性肾损伤患者的一种治疗选择,然而,在PD治疗期间选择合适的免疫抑制剂至关重要。